Malaysian Genomics Resource Centre Bhd (XKLS:0155) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Malaysian Genomics Resource Centre Bhd EBITDA Margin % Related Terms
Malaysian Genomics Resource Centre Bhd EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd EBITDA Margin % Chart
Malaysian Genomics Resource Centre Bhd Annual Data
XKLS:0155 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malaysian Genomics Resource Centre Bhd EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a EBITDA Margin % of 54.56% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. According to the industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #87 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 42.6%.
Is Malaysian Genomics Resource Centre Bhd's EBITDA Margin % too high?
Malaysian Genomics Resource Centre Bhd's current EBITDA Margin % is 54.56%. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Malaysian Genomics Resource Centre Bhd's value of 54.56% is 949.2% above this industry median. Based on the distribution chart, Malaysian Genomics Resource Centre Bhd ranks #87 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #87 out of 204 companies for EBITDA Margin %. This puts Malaysian Genomics Resource Centre Bhd in the upper half of its industry. The industry median EBITDA Margin % is 5.20. Malaysian Genomics Resource Centre Bhd's value of 54.56% is 949.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Malaysian Genomics Resource Centre Bhd's current EBITDA Margin % of 54.56% is 949.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malaysian Genomics Resource Centre Bhd's current EBITDA Margin % is 54.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.30, compared to a current price of RM0.27 — trading 10% below its estimated fair value. The current EBITDA Margin % is 54.56% and 949.2% above the Medical Diagnostics & Research industry median of 5.20. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current EBITDA Margin % is 54.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be undervalued.
The current stock price of RM0.27 is trading 10% below its estimated GF Value™ of RM0.30.
GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0155:
EBITDA Margin %: 54.56%
GF Value™: RM0.30 vs. price of RM0.27 (10% below fair value)
Industry Position: 949.2% above the Medical Diagnostics & Research median (#87 of 204)
No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Malaysian Genomics Resource Centre Bhd Business Description
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
47GF Score
Get the complete analysis for XKLS:0155
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0155 has been successfully added to your 
